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Predictors of Liver Fat and Stifness 
in Non-Alcoholic Fatty Liver 
Disease (NAFLD) – an ͷͷ-Year 
Prospective Study
Susanna Lallukka  ͷ,͸, Sanja Sädevirtaͷ,͸, Markus T. Kallioͷ,͸, Panu K. Luukkonenͷ,͸,  
You Zhouͷ,͹, Antti Hakkarainenͺ, Nina Lundbomͺ, Marju Orho-Melanderͻ &  
Hannele Yki-Järvinenͷ,͸
Liver fat can be non-invasively measured by proton magnetic resonance spectroscopy (ͷH-MRS) and 
ibrosis estimated as stifness using transient elastography (FibroScan). There are no longitudinal data 
on changes in liver fat in Europids or on predictors of liver stifness using these methods. We determined 
liver fat (ͷH-MRS) and clinical characteristics including features of insulin resistance at baseline and 
after a median follow-up period of ͷͷ.͹ (range ͽ.͹–ͷ͹.ͺ) years in Ϳͽ Finnish subjects. Liver stifness was 
measured at ͷͷ.͹ years. Liver fat content decreased by ͻ% (p < Ͷ.Ͷͻ) over time. Values at baseline and 
ͷͷ.͹ years were closely interrelated (r = Ͷ.;ͷ, p < Ͷ.ͶͶͷ). Baseline liver fat (OR ͷ.͹͸; Ϳͻ%CI: ͷ.ͷͻ–ͷ.ͻͶ) 
and change in BMI (OR ͷ.ͼͽ; Ϳͻ%CI: ͷ.͸ͺ–͸.͸ͻ) were independent predictors of liver fat at ͷͷ.͹ years 
(AUROC Ͷ.ͿͶ; Ϳͻ%CI: Ͷ.;͹–Ͷ.Ϳͼ). Baseline liver fat (AUROC Ͷ.;ͺ; Ϳͻ%CI: Ͷ.ͽͼ–Ͷ.Ϳ͸) predicted liver fat 
at ͷͷ.͹ years more accurately than routinely available parameters (AUROC Ͷ.ͽͼ; Ϳͻ%CI: Ͷ.ͼͻ–Ͷ.;ͼ, 
p = Ͷ.Ͷ͸). At ͷͷ.͹ years, ͸Ϳ% of the subjects had increased liver stifness. Baseline liver fat (OR ͸.ͷͽ; 
Ϳͻ%CI: ͷ.Ͷͻ–ͺ.ͺͼ) was an independent predictor of increased liver stifness. These data show that liver 
fat is more important than the associated metabolic abnormalities as the predictor of future liver fat 
and ibrosis.
Non-alcoholic fatty liver disease (NAFLD) covers a range of conditions from simple steatosis (non-alcoholic 
fatty liver, NAFL) to non-alcoholic steatohepatitis (NASH) and ibrosis1. NAFL has been considered a benign 
and non-progressive condition2. Recent paired-biopsy studies in NAFLD patients have challenged this dogma 
by showing that NAFL can progress to NASH and ibrosis3–5, although the rate of progression is slow (1 stage 
over 14.3 years)6. It is unclear whether steatosis and the associated hypoxia and cell death around the central 
venous vein result in ibrosis via stellate cell activation7,8 or whether features of insulin resistance associated with 
‘Obese/Metabolic’ NAFLD are of importance for ibrogenesis9,10. In support of the role of steatosis alone, patients 
with NAFLD due to genetic risk variants in patatin-like phospholipase domain-containing 3 (PNPLA3), trans-
membrane 6 superfamily member 2 (TM6SF2) and membrane bound O-acyltransferase domain containing 7 
(MBOAT7) develop the full spectrum of NAFLD while they are neither insulin resistant nor at high risk of type 2 
diabetes or cardiovascular diseases11–14.
he natural course of steatosis was recently characterized using proton magnetic resonance spectroscopy 
(1H-MRS), the state-of-the-art technique to quantify steatosis, in 565 Chinese subjects followed for 3.9 years15. 
Fatty liver developed in 14% of the subjects during the follow-up15. Kim et al. studied 76 obese youth of mixed 
ethnic origin for an average of 1.9 years and found liver fat measured by magnetic resonance imaging to remain 
unchanged during the follow-up16. Similar data are not available in Europid subjects.
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Liver fibrosis can be non-invasively estimated using 1D ultrasonography transient elastography (TE; 
FibroScan, Echosens, Paris, France). he recent EASL-EASD-EASO Clinical Practice Guidelines for manage-
ment of NAFLD and EASL-ALEH Clinical Practice Guidelines for evaluation of liver disease severity concluded 
that this technique is an acceptable non-invasive procedure for identiication of cases at high risk of advanced 
ibrosis and cirrhosis1,17. Liver stifness measurement (LSM) by TE predicts overall and liver-related mortality in 
NAFLD18 but we are not aware of longitudinal studies searching for predictors of increased liver stifness.
In the present study, we examined the natural course of liver triglyceride content using1H-MRS in 97 Finnish 
subjects during an 11-year follow-up period, and determined which baseline factors predict NAFLD (liver tri-
glyceride content exceeding 5.6%) and liver stifness measured by TE. We were particularly interested to deter-
mine whether it is baseline liver fat or some feature of obesity/insulin resistance that best predicts liver stifness.
Study Subjects and Design
Study subjects. We invited volunteers who had previously been participating in metabolic studies addressing 
liver fat content in our laboratory between years 1998 and 200419–24. he subjects for the metabolic studies had been 
recruited based on newspaper advertisements and by contacting physicians in the Helsinki University Hospital 
region. Inclusion criteria at baseline were i) age 18 to 75 years, ii) no known acute or chronic disease except for 
obesity, hypertension, NAFLD or type 2 diabetes based on medical history, physical examination and standard labo-
ratory tests (blood counts, serum creatinine, thyroid-stimulating hormone, electrolyte concentrations) and electro-
cardiogram, and iii) alcohol consumption less than 20 g per day in women and less than 30 g in men. he response 
rate was 73%. At follow-up, we examined 109 subjects of whom 12 were excluded because of excessive use of alcohol 
at the follow-up visit (n = 9), use of herbal medicinal products (n = 1) or cortisone (n = 1), or who underwent bari-
atric surgery (n = 1). he number of subjects studied was thus 97. Between the two study visits, the subjects received 
their usual treatment in the outpatient clinic if needed but did not participate in any intervention studies.
he study was conducted in accordance with the Declaration of Helsinki. Each participant provided written 
informed consent ater being explained the nature and potential risks of the study. he ethics committee of the 
Helsinki University Hospital approved the study protocol.
Study design. Baseline visit. At the baseline visit, medical history was obtained and a physical examination 
was performed. Fasting blood samples were taken for measurement of total blood counts and plasma creati-
nine, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyltransferase (GGT), 
high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol, triglyceride, glucose, glycosylated 
hemoglobin A1C (HbA1C), albumin, potassium, sodium, serum insulin and free fatty acid (FFA) concentrations. 
Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated from the formula: fasting glu-
cose (mmol/l) × fasting insulin (mU/l)/22.525. he NAFLD ibrosis score was calculated based on knowledge of 
age, body mass index (BMI), impaired fasting glucose/diabetes status, concentrations of AST, ALT and albumin, 
and platelet count as described26. A pregnancy test in serum was performed in women of childbearing age. Proton 
magnetic resonance spectroscopy (1H-MRS) was used for measurement of liver fat content.
Follow-up visit. At this visit, medical history and physical examination were repeated. Fasting blood samples 
were taken for measurement of the same biochemical parameters and in the same laboratory as at baseline. In 
addition, antibodies against hepatitis A (HAVAbG and HAVAbM), B (HBcAb) and C (HCVAb), transferrin sat-
uration, and anti-smooth muscle, anti-nuclear and anti-mitochondrial antibodies were measured. A pregnancy 
test in serum was performed in women of childbearing age. We also obtained blood samples for genotyping study 
subjects for NAFLD risk variants in PNPLA3 at rs738409, TM6SF2 at rs58542926 and MBOAT7 at rs641738. 
hereater, a 2-hour oral glucose tolerance test (OGTT) was performed in non-diabetic subjects. Measurement 
of liver fat content by 1H-MRS was repeated. In addition, 92 subjects participated in a separate visit during which 
liver stifness was measured using TE ater an overnight fast. We used non-invasive imaging methods to measure 
liver steatosis and to estimate ibrosis as it was considered unethical to perform invasive liver biopsies without 
clinical indication in most of the study subjects.
Results
Liver fat content. Baseline characteristics of the study subjects are shown in Table 1. he median duration 
of follow-up was 11.3 and ranged from 7.3 to 13.4 years. Liver fat content decreased slightly by 5% from a median 
of 6.1% (25–75th percentile: 1.9–14.0%) at baseline to 5.8% (1.9–13.1%) at 11.3 years (p = 0.02). Individual values 
at baseline and at 11.3 years were highly interrelated (r = 0.81, p < 0.0001, Fig. 1). Of subjects without NAFLD 
at baseline, 79% remained free of NAFLD, and 73% of those with NAFLD at baseline still had NAFLD ater the 
11.3-year follow-up period.
In univariate analysis, of baseline parameters, measures of obesity, concentrations of fasting glucose, insulin, tri-
glycerides, HDL cholesterol and liver enzymes, and liver fat content predicted liver fat content at 11.3 years (Table 2).
In a multiple binary logistic regression model, liver fat content remained the only independent predictor of 
NAFLD at 11.3 years (odds ratio: 1.22, 95% conidence interval (CI): 1.11–1.34, p < 0.001; Table 3). To determine 
how well routinely available clinical variables at baseline predict liver fat at 11 years, we included in another logis-
tic regression model signiicantly associated baseline variables other than liver fat. In this model, baseline waist 
circumference and plasma ALT were independent predictors of NAFLD at 11.3 years (Table 3). he area under 
the receiver operating characteristic curve (AUROC) of the irst model including baseline liver fat (0.84, 95% 
CI: 0.76–0.92, p < 0.0001 for this AUROC) was signiicantly greater than that of the latter model including only 
routinely available parameters (0.76, 95% CI: 0.65–0.86, p < 0.0001 for this AUROC and p = 0.02 for comparison 
between the models) (Fig. 2).
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he relationship between changes in various parameters and liver fat content at follow-up are shown in 
Supplementary Table 1. When changes were included in the model also containing baseline parameters, of 
changes only that  in BMI remained an independent predictor of NAFLD at 11.3 years (Table 3). he AUROC 
of this model was 0.90 (95% CI: 0.83–0.96, p < 0.0001), which was not signiicantly better than that containing 
only baseline liver fat content (Fig. 2). he relationship between change in liver fat and changes in BMI, fasting 
triglycerides, HOMA-IR and ALT concentrations are depicted in Supplementary Fig. 1.
All Low liver stifness (71%) Increased liver stifness (29%)
Baseline Baseline Follow-up Baseline Follow-up
Age (years) 44 ± 1 42 ± 1 53 ± 1### 46 ± 2 57 ± 2###
Gender (Men/Women) 46/51 23/29 — 11/10 —
Body composition
        Weight (kg) 84.8 ± 1.5 79.5 ± 1.6 82.5 ± 1.9# 86.7 ± 3.0* 88.9 ± 2.8
        BMI (kg/m2) 29.0 ± 0.5 27.1 ± 0.5 28.1 ± 0.6# 29.6 ± 1.2* 30.4 ± 1.2
        Waist circumference (cm) 99.0 ± 1.3 93.9 ± 1.4 93.4 ± 1.7 101.3 ± 2.8* 103.1 ± 2.8*
        Body fat (%) 30.2 (22.2–35.8) 27.6 (20.6–34.8) 30.8 (24.7–37.8)### 30.2 (23.0–36.2) 32.4 (26.0–38.5)##
        Liver fat (%) 6.1 (1.9–14.0) 4.1 (1.4–9.1) 3.5 (1.3–8.4)
10.8 (4.2–
19.9)**
13.4 (4.2–17.3)**
        Liver fat ≥5.56% (%) 55% 44% 40% 71%* 62%*
Blood pressure
        Systolic (mmHg) 125 ± 2 125 ± 2 141 ± 3### 127 ± 3 146 ± 3##
        Diastolic (mmHg) 82 ± 1 80 ± 1 89 ± 2### 84 ± 2 90 ± 2#
Measures of glucose homeostasis
        fP-glucose (mmol/l) 5.8 (5.3–6.4) 5.6 (5.2–6.1) 5.4 (4.9–5.8)### 5.6 (5.1–6.3) 5.6 (4.9–6.4)
        fS-insulin (mU/l) 7.0 (5.0–12.0) 6.5 (4.0–9.0) 5.4 (3.1–10.3) 9.0 (5.5–14.8)* 11.1 (6.1–12.6)*
        HOMA-IR 2.0 (1.2–3.5) 1.5 (1.1–2.4) 1.3 (0.7–2.4) 2.6 (1.4–3.7) 2.9 (1.6–3.3)*
        HbA1C (%) 5.7 (5.3–6.1) 5.5 (5.3–6.0) 5.6 (5.3–6.0) 5.9 (5.4–6.1) 6.0 (5.5–6.7)
#,
*
        Type 2 diabetes (%) 22% 15% 19% 24% 43%*
         Glucose-lowering medication (%) 14% 8% 23%# 14% 24%
        Insulin (%) 8% 6% 10% 10% 14%
Lipids
        fP-Triglycerides (mmol/l) 1.3 (0.9–1.9) 1.3 (0.9–1.7) 1.1 (0.8–1.5) 1.5 (1.0–2.6) 1.3 (0.9–2.2)
        fP-HDL cholesterol (mmol/l) 1.3 (1.1–1.5) 1.3 (1.1–1.6) 1.3 (1.2–1.6)# 1.2 (1.1–1.4) 1.2 (1.1–1.5)
        fP-LDL cholesterol (mmol/l) 3.1 (2.4–3.8) 3.0 (2.3–3.8) 2.9 (2.4–3.6) 3.0 (2.4–3.5) 3.0 (2.1–3.8)
        fS-FFA (µmol/l) 689 ± 24 656 ± 29 500 ± 25### 692 ± 46 536 ± 44#
        Lipid medication (%) 9% 4% 35%### 14% 14%
Liver enzymes and function tests
        P-ALT (U/l) 28 (20–48) 27 (19–49) 28 (21–37) 36 (22–48) 40 (21–51)
        P-AST (U/l) 27 (22–38) 27 (22–38) 29 (25–36) 28 (25–40) 33 (28–50)*
        P-GGT (U/l) 25 (15–46) 18 (14–41) 23 (16–43) 30 (19–60) 31 (19–60)
        AST/ALT ratio 0.91 (0.69–1.10) 0.95 (0.66–1.12) 1.04 (0.86–1.21)# 0.90 (0.74–1.09) 1.03 (0.94–1.22)#
        P-Albumin (g/l) 41.1 ± 0.4 41.3 ± 0.5 38.8 ± 0.3### 41.9 ± 1.0 38.7 ± 0.5
        B-platelet count (109/l) 234 (194–269) 231 (202–272) 235 (204–277) 241 (194–270) 231 (203–258)
B-leukocyte count (109/l) 5.8 ± 0.2 5.5 ± 0.2 5.5 ± 0.2 6.5 ± 0.3* 6.7 ± 0.3**
Risk variants for NAFLD
        PNPLA3 (148II/148IM/148MM) 54/33/10 30/15/7 — 12/8/1 —
        TM6SF2 (CC/CT/TT) 74/17/1 39/10/0 — 17/3/1 —
        MBOAT7 (CC/CT/TT) 35/43/14 17/26/6 — 8/7/6 —
Table 1. Characteristics of 97 study subjects and of those with low and increased liver stifness at follow-up. 
Data are shown as number, percent, mean ± standard error of mean or median (the 25th–75th percentiles). 
#p < 0.05, ##p < 0.005, ###p < 0.0005 as compared to baseline within the group. *p < 0.05, **p < 0.005, 
***p < 0.0005 as compared to the ‘Low liver stifness’ group at the same visit. Abbreviations: ALT, alanine 
aminotransferase; AST, aspartate aminotransferase; B, blood; BMI, body mass index; FFA, free fatty acid; 
fP, fasting plasma; fS, fasting serum; GGT, gamma-glutamyl transferase; HbA1C, glycosylated hemoglobin 
A1C; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; LDL, 
low-density lipoprotein; MBOAT7, membrane bound O-acyltransferase domain containing 7; NAFLD, non-
alcoholic fatty liver disease; P, plasma; PNPLA3, patatin-like phospholipase domain-containing protein 3; 
TM6SF2, transmembrane 6 superfamily member 2.
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We also created a multiple linear regression equation to allow prediction of liver fat content at follow-up with 
the help of baseline liver fat (Model 1 in Supplementary Table 2). Exclusion of baseline liver fat worsened the 
model considerably (Model 2 in Supplementary Table 2). In multiple linear regression analysis, which included 
signiicant baseline parameters and changes during follow-up, baseline liver fat and changes in BMI and HbA1C 
remained signiicant independent predictors and explained 74% (p < 0.001) of the variation in liver fat content at 
11 years (Model 3 in Supplementary Table 2).
Liver stifness and NAFLD ibrosis score. At follow-up, 29% of the subjects had increased liver stifness 
(Table 1). In these subjects, the median LSM was 10.4 kPa (25–75th percentile: 9.5–14.3 kPa) measured with the M 
probe (n = 11) and 10.3 kPa (25–75th percentile: 7.9–12.3 kPa) measured with the XL probe (n = 10) at follow-up. 
In subjects with low liver stifness at follow-up, the median LSM with the M probe was 5.4 kPa (25–75th percen-
tile: 4.3–6.8 kPa; n = 42) and with the XL probe 5.8 kPa (25–75th percentile: 4.2–6.6 kPa; n = 10). Subjects who 
had increased liver stifness at follow-up were signiicantly more obese, had wider waist circumferences, and had 
higher serum insulin concentrations and blood leukocyte counts at baseline than subjects whose liver stifness 
remained below the cut-of values (Table 1). Baseline liver fat content was signiicantly higher in subjects with 
(10.6%, 4.0–20.0) than without (4.1%, 1.4–9.7, p < 0.001) increased stifness. he NAFLD ibrosis score increased 
signiicantly during 11 years from a median of −2.202 (−2.713 to −1.294) at baseline to −0.989 (−1.776 to 
−0.095, p < 0.001) at follow-up. Aging explained 32% of this change. he increase in NAFLD ibrosis score dur-
ing 11 years was signiicant even if age was kept constant (−1.379 (−2.152 to −0.510) at follow-up, p < 0.001 for 
change).
Baseline parameters, which were signiicantly associated with increased liver stifness at follow-up (Table 2), 
were entered in multiple binary logistic regression analysis. Baseline liver fat content remained an independ-
ent predictor of increased liver stifness at follow-up (Table 3). he AUROC of this model was 0.74 (95% CI: 
0.61–0.87, p = 0.002).
Liver biopsies. Liver biopsies were obtained in seven patients with clinical indication. he histological fea-
tures of these biopsies are listed in Table 4.
Discussion
In this longitudinal study, we measured liver fat content using 1H-MRS at an interval of around 11 years. Although 
mean liver fat content decreased signiicantly by 5%, baseline and follow-up values were highly interrelated. Of 
subjects without NAFLD, 79% remained free of NAFLD while NAFLD persisted in 73% of those with NAFLD 
at baseline. Baseline liver fat content and the change in BMI were the best predictors of liver fat at follow-up in 
multivariate analyses. At 11 years, 29% of the subjects had increased liver stifness. At baseline, these subjects were 
more obese, had wider waist circumferences, and had higher liver fat content and blood leukocyte counts than 
subjects with more elastic livers. In multivariate analysis, baseline liver fat content remained the only independent 
predictor of liver stifness.
Liver fat at baseline and follow-up were signiicantly correlated (r = 0.81) in the present study. his correlation 
coeicient was identical to that observed in 76 obese youth followed for 1.9 years16. In the study in Hong-Kong, 
the correlation coeicient between baseline and follow-up liver fat values was 0.39 in subjects without and 0.50 in 
Figure 1. he relationship (Pearson’s correlation coeicient, r) between liver fat content measured by 1H-MRS 
at baseline and at 11 years.
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those with NAFLD at baseline15. Consistent with the current data, a study using ultrasound to diagnose NAFLD 
found 81% of 147 subjects without steatosis at baseline to remain free of NAFLD, while 64% of 66 subjects with 
NAFLD at baseline still had NAFLD ater a 7-year period of follow-up27. Although individual values were closely 
correlated at baseline and follow-up, liver fat content decreased slightly and signiicantly. his is in line with 
paired-biopsy studies, in which steatosis grade signiicantly decreased while ibrosis progressed during 3.2 years 
of follow-up of 103 subjects of unspeciied ethnic origin28, during 6.4 years of follow-up of 132 Italian subjects29 
and during 13.7 years of follow-up of 68 Swedes30. In 52 Chinese subjects with NAFLD, steatosis grade increased 
signiicantly while ibrosis stage remained stable during 3 years4.
In addition to baseline liver fat, several measures of obesity and concentrations of fasting glucose, insulin, 
triglycerides and HDL cholesterol predicted liver fat measured by 1H-MRS at follow-up in univariate analyses. 
hese data, which to our knowledge are the irst in Europid adults, resemble those in Chinese15. In the latter study, 
subjects who developed NAFLD diagnosed by 1H-MRS were more obese and had higher glucose and triglyceride 
concentrations and lower concentrations of HDL cholesterol than those who did not develop a fatty liver15. Most 
studies assessing steatosis by ultrasound have been performed in Asians31–34. In these studies, baseline obesity31–33, 
age32,33, components of metabolic syndrome32,33 and serum ferritin34 predicted NAFLD. he change in BMI was 
the only signiicant predictor of the change in liver fat during 11 years in the present study. Similarly, weight gain 
was associated with development and weight loss with remission of NAFLD diagnosed by ultrasound in 213 
Israeli subjects27.
Liver fat content (n = 91) Liver stifness (n = 73)
r p-value OR (95% CI)a p-value
Age (years) 0.352 0.001 1.06 (0.99–1.12) 0.09
Male gender −0.156 0.13 1.39 (0.50–3.83) 0.53
Body composition
      Liver fat content (log) 0.809 <0.001 2.48 (1.27–4.84) 0.01
      Waist circumference (cm) 0.481 <0.001 1.06 (1.01–1.11) 0.02
      Waist-to-Hip Ratio (per SD) 0.359 0.001 2.04 (1.10–3.79) 0.03
      BMI (kg/m2) 0.412 <0.001 1.15 (1.02–1.30) 0.03
      Weight (kg) 0.306 0.003 1.05 (1.00–1.10) 0.03
      Body fat percent (log) 0.422 <0.001 1.26 (0.76–2.08) 0.37
Measures of glucose homeostasis
      HOMA-IR (log) 0.560 <0.001 1.70 (0.95–3.04) 0.07
      fS-insulin (log) 0.512 <0.001 1.96 (1.06–3.63) 0.03
      HbA1C (log) 0.281 0.007 1.25 (0.74–2.11) 0.41
      fP-glucose (log) 0.259 0.01 1.04 (0.62–1.73) 0.89
Blood leukocyte count (log) 0.253 0.02 2.12 (1.19–3.78) 0.01
Liver enzymes
      P-ALT (log) 0.448 <0.001 1.14 (0.69–1.89) 0.61
      AST/ALT ratio (log) −0.419 <0.001 0.93 (0.60–1.61) 0.93
      P-GGT (log) 0.375 0.001 1.40 (0.82–2.40) 0.21
      P-AST (log) 0.271 0.009 1.18 (0.73–1.92) 0.49
Lipids
      fP-Triglycerides (log) 0.371 <0.001 1.47 (0.88–2.44) 0.13
      fP-HDL cholesterol (log) −0.347 0.001 0.59 (0.34–1.05) 0.07
      fP-LDL cholesterol (mmol/L) 0.046 0.67 0.91 (0.51–1.63) 0.75
      fS-FFA (µmol/L) 0.197 0.07 1.00 (1.00–1.00) 0.50
Risk variants for NAFLD
      PNPLA3 (148II/148IM/148MM) 0.150 0.16 1.02 (0.37–2.85)b 0.73
      TM6SF2 (CC/CT/TT) −0.001 0.99 0.92 (0.25–3.34)b 0.90
      MBOAT7 (CC/CT/TT) 0.056 0.61 1.30 (0.63–2.68) 0.48
      Number of risk alleles 0.129 0.25 1.15 (0.73–1.81) 0.54
Table 2. Univariate analyses for baseline predictors of liver fat and increased stifness at follow-up. aOR is 
calculated per unit, number or if logarithmic transformed per standard deviation (SD). b148IM and 148MM/CT 
and TT groups are combined. Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; 
BMI, body mass index; CI, conidence interval; FFA, free fatty acids; fP, fasting plasma; fS, fasting serum; GGT, 
gamma-glutamyl transferase; HbA1c, glycosylated hemoglobin A1c; HDL, high-density lipoprotein; HOMA-IR, 
homeostasis model assessment of insulin resistance; LDL, low-density lipoprotein; MBOAT7, membrane 
bound O-acyltransferase domain containing 7; OR, odds ratio; P, plasma; PNPLA3, patatin-like phospholipase 
domain-containing protein 3; r, Pearson’s correlation coeicient; TM6SF2, transmembrane 6 superfamily 
member 2.
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To our knowledge, this is the irst longitudinal study identifying predictors of increased liver stifness in 
NAFLD. We did not perform LSM at baseline, which is a limitation. However, at least when judged from the 
NAFLD ibrosis score, ibrosis did signiicantly worsen during the follow-up, even when normalized for age. Liver 
fat content was an independent predictor of liver stifness at the end of the 11-year follow-up period. he data are 
consistent with paired-biopsy studies showing that steatosis predicts ibrosis3,5,6.
he ability of liver fat but not metabolic features to predict stifness 11 years later may give hints of the patho-
genesis of ibrosis. It is well established that patients with NAFLD due to the genetic risk variants in PNPLA335, 
TM6SF236 and MBOAT713 are at risk of ibrosis but these patients are neither more obese nor insulin resist-
ant compared to non-carriers of the variants37–39. his would suggest that steatosis, the common denominator 
between ‘Obese/Metabolic’ NAFLD and NAFLD due to the risk variants, rather than insulin resistance could 
facilitate the development of ibrosis. In liver lobules, fat accumulates and hepatocytes undergo cell death (bal-
looning) around the central vein40. his process leads to activation of hepatic stellate cells and perisinusoidal 
deposition of collagen again starting from the central venous area8,40. his pathophysiology could explain why 
steatosis rather than the associated metabolic features predicts ibrosis, although measurement of steatosis is nei-
ther necessary nor suicient to detect ibrosis.
Strengths of our study include a long follow-up period and use of a state-of-the-art quantitative method to 
measure of liver fat with 1H-MRS. he data are also the irst to describe predictors of increased liver stifness 
associated with NAFLD. An important limitation of our study is that the study subjects were not selected from a 
population-based sample but were recruited by newspaper advertisements and by contacting local physicians and 
thus selection bias may exist. Our study is also underpowered to detect efects of the genetic risk variants on liver 
fat content. Furthermore, liver biopsies were only available from subjects in whom a liver biopsy was considered 
to be clinically justiied.
We conclude that liver fat decreases slightly although NAFLD status remains markedly stable over an 11-years. 
Baseline liver fat content is the best predictor of both liver fat and stifness during 11 years of follow-up while 
routinely available clinical and biochemical parameters are signiicantly less accurate predictors. hese data sup-
port the view that steatosis rather than the associated metabolic abnormalities is important in the pathogenesis 
of ibrosis.
Methods
Measurement of liver fat using proton magnetic resonance spectroscopy (ͷH-MRS). he liver 
fat content was measured using three generations of 1.5 Tesla clinical scanners (Magnetom Vision, Sonata and 
Avanto, Siemens Healthcare Diagnostics, Erlangen, Germany). he intensity diferences arising from various 
acquisition parameters and localization techniques had to be normalized. T1-weighted high-resolution magnetic 
AUROC B SE P-value OR (95% CI)
Models to predict NAFLD
‘All baseline parameters’ (Model 1)* 0.84 (0.76–0.92), p < 0.0001
     Baseline liver fat (per 1%) 0.198 0.049 <0.001 1.22 (1.11–1.34)
     Constant −1.519 0.421 <0.001 0.22
‘Baseline parameters except for liver fat’ (Model 2)# 0.76 (0.65–0.86), p < 0.0001
     Baseline waist circumference (per 1 cm) 0.065 0.023 0.005 1.07 (1.02–1.12)
     Baseline P-ALT (per 10 U/L) 0.27 0.125 0.03 1.31 (1.03–1.67)
     Constant −7.375 2.314 0.001 0.001
‘All baseline parameters and all changes except for 
liver fat’ (Model 3)°
0.90 (0.83–0.96), p < 0.0001
     Baseline liver fat (per 1%) 0.274 0.067 <0.001 1.32 (1.15–1.50)
     Change in BMI (per 1 kg/m2) 0.513 0.152 0.001 1.67 (1.24–2.25)
     Constant −2.768 0.678 <0.001 0.063
Model to predict liver stifness**
     Baseline liver fat (log, per SD) 0.74 (0.61–0.87), p = 0.002 0.773 0.368 0.04 2.17 (1.05–4.46)
     Baseline leukocyte count (log, per SD) 0.598 0.327 0.07 1.82 (0.96–3.45)
     Constant −0.985 0.313 0.002 0.373
Table 3. Multiple binary logistic regression models to predict NAFLD and increased liver stifness. 
*Model 1 (‘All baseline parameters’) included baseline age, BMI, waist circumference, plasma ALT, fasting 
plasma triglyceride, blood leukocyte count, HOMA-IR and baseline liver fat content. #Model 2 (‘Baseline 
parameters except for liver fat’) included all parameters in Model 1 except for baseline liver fat. °Model 3 (‘All 
baseline parameters and changes except for liver fat’) including parameters in Model 1 and changes in waist 
circumference, BMI, HbA1c and blood leukocyte count during 11 years. **Model predicting liver stifness 
included baseline age, weight, waist-to-hip ratio, fasting serum insulin (log), fasting plasma HDL cholesterol 
(log), blood leukocyte count (log) and liver fat content (log). ALT, alanine aminotransferase; AUROC, area 
under the receiver operating characteristic curve; B, coeicient; BMI, body mass index; CI, conidence 
interval; HbA1C, glycosylated hemoglobin A1C; HDL, high-density lipoprotein; HOMA-IR, homeostasis model 
assessment of insulin resistance; log, logarithmic transformed; NAFLD, non-alcoholic fatty liver disease; OR, 
odds ratio; SD, standard deviation; SE, standard error.
www.nature.com/scientificreports/
7SCIENTIFIC REPORTS | ͽ: 14561  | DOI:ͷͶ.ͷͶ͹;/sͺͷͻͿ;-Ͷͷͽ-ͷͺͽͶͼ-Ͷ
resonance imaging scans were collected using a standard 1H body coil. he 1H-MRS voxel of interest (8 to 27 cm3) 
was carefully located within the right lobe of the liver avoiding subcutaneous fat, large vessels, bile ducts and the 
gall bladder. Localization was performed using the STEAM sequence with echo time (TE)/mixing time (TM)/rep-
etition time (TR) of 20/30/3000 ms and 32 acquisitions for Vision measurements and the PRESS sequence with 
TE/TR of 30/3000 ms and 16 acquisitions for Sonata and Avanto measurements. Subjects were breathing normally 
during the data collection. All spectra were analyzed with the MRUI/jMRUI sotware using VARPRO/AMARES 
(available at www.mrui.uab.es/mrui/). he intensities of the peaks resonating from the protons of water, and 
protons of methylene (CH2)n-2 groups in the fatty acid chains were determined using line-shape itting with prior 
knowledge. Signal intensities were corrected for T1 and T2 relaxation using the equation Im = I0 exp(−TE/T2) 
*[1−exp(−(TR−TM−0.5TE)/T1)]*exp(−TM/T1) for Vision data and the equation Im = I0 exp(−TE/T2) for 
Sonata and Avanto data. T1 of 600 ms41 and 300 ms42 and experimentally determined T2 of 46 ms and 58 ms 
were used for water and fat, respectively. Liver fat content was expressed as a ratio of signal from methylene group 
to total signal of methylene and water. Liver fat content was converted from signal ratio to a weight fraction, 
applying method validated by Longo et al.43 and Szczepaniak et al.44. he following experimentally determined 
factors were used: i) the ratio of the number of lipid protons in the itted (CH2)n-2 signal to the total number of 
lipid protons is 0.633245; ii) proton densities of fat and water are 111 and 111 mol/l, respectively; iii) 1 g liver tissue 
contains 711 mg water; iv) densities of the liver tissue, fat in the liver, and water are 1.051 g/ml, 0.900 g/ml, and 
Figure 2. he receiver operating characteristic (ROC) curves of models to predict NAFLD (liver fat 
≥5.56%) at follow-up. Models included signiicant predictors from univariate analyses: baseline age, BMI, 
waist circumference, fasting plasma triglyceride, blood leukocyte count, HOMA-IR, plasma ALT and liver 
fat content, and changes in waist circumference, BMI, HbA1C and blood leukocyte count. Model 1 (green) 
included all signiicant baseline predictors: baseline liver fat content was independent predictor of NAFLD at 
follow-up with AUROC of 0.84 (95% CI: 0.76-0.92), p < 0.0001. Model 2 (red) included all signiicant baseline 
predictors except for liver fat content: baseline waist circumference and plasma ALT were independent predictors 
of NAFLD at follow-up with AUROC of 0.76 (95% CI: 0.65-0.86), p < 0.0001. Model 3 (blue) included all 
signiicant baseline predictors and changes during a follow-up period: baseline liver fat content and change in BMI 
remained independent predictors of NAFLD at follow-up with AUROC of 0.90 (95% CI: 0.83-0.96), p < 0.0001. 
Comparison between models using the method of DeLong et al.: Model 1 (p = 0.02) and Model 3 (p = 0.006) were 
signiicantly better than Model 2 to predict NAFLD at follow-up. he diference between Model 1 and Model 3 
was not signiicant (p = 0.07). Abbreviations: ALT, alanine aminotransferase; AUROC, area under the receiver 
operating characteristic curve; BMI, body mass index; CI, conidence interval; HbA1C, glycosylated hemoglobin 
A1C; HOMA-IR, homeostasis model assessment of insulin resistance; NAFLD, non-alcoholic fatty liver disease..
Liver stifness (kPa) Steatosis (%) Ballooning (yes/no) Lobular inlammation (yes/no) Stage of ibrosis
1. 6.6a 60 Yes Yes 1
2. 7.0a 10 No No 0
3. 10.2a 80 Yes Yes 1
4. 10.4a 60 Yes Yes 2
5. 10.4b 30 Yes Yes 2
6. 28.4b 40 No No 2
7. 72.0b 30 No No 4
Table 4. Liver stifness and histological assessment of liver biopsies (n = 7). aMeasured using the XL probe. 
bMeasured using the M probe.
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1.000 g/ml; respectively. he measurement has been validated against histologically determined lipid content46 
and against estimates of fatty degeneration or iniltration by x-ray computer-assisted tomography21. A physicist 
who was unaware of any of the clinical data analyzed all spectra. NAFLD was deined as liver fat >5.56% by 1H-
MRS as in the Dallas Heart Study44.
Liver stiffness measurement (LSM) using transient elastography (TE). LSM was used as a 
non-invasive test estimating liver ibrosis and was measured when the patients were lying supine with their right 
arm in maximal abduction using TE (FibroScan, Echosens, Paris, France). Two experienced physicians (S.L. and 
P.K.L.) performed LSMs using the same protocol. he tip of the probe transducer was covered with gel and placed 
on the skin at the level of the right lobe of the liver. he depth of the measurement was 25–65 mm below the skin 
surface using the M probe and 35–75 mm using the XL probe. LSM was irst performed with the M probe. If 
obesity prevented adequate measurement, the XL probe was used. We used the cut-of values of 8.7 kPa with the 
M probe and 7.2 kPa with the XL probe for clinically signiicant stage 3–4 ibrosis, as recommended47. Subjects in 
whom 10 acquisitions were successful and interquartile range divided by median (IQR/median) was less than 0.3 
were included in analyses. LSM failed with both probes in eight subjects. he results are expressed as the median 
value of ten successful measurements in kilopascal (kPa).
Liver biopsies. When clinically indicated, a percutaneous liver biopsy was obtained under ultrasound guid-
ance using a 16 G BioPince Full Core Biopsy instrument (Argon Medical Devices, Athens, TX). All biopsies 
were > 20 mm in length and sent to the pathologist for histological assessment. Histology was analyzed by an 
experienced liver pathologist in a blinded fashion according to the criteria proposed by Brunt et al.40.
Genotyping of PNPLA3, TM6SF2 and MBOAT7 risk variants. Genomic DNA was extracted from 
whole blood using the Autopure LS (Qiagen, Hilden, Germany). All three single-nucleotide polymorphisms 
(SNP; PNPLA3 at rs738409, C>G/I148M; TM6SF2 at rs58542926, C>T/E167K; and MBOAT7 at rs641738, C>T) 
were genotyped by TaqMan PCR method (Applied Biosystems, Foster City, CA) according to manufacturer’s 
instructions. Post-PCR allelic discrimination was carried out measuring allele-speciic luorescence on an ABI 
Prism Sequence Detection System ABI 7900HT (Applied Biosystems). he success rate for genotyping was >95% 
for all three SNPs and the genotypes of all three SNPs were in Hardy–Weinberg equilibrium.
Analytical procedures. Fasting plasma glucose was measured using a hexokinase method on an autoana-
lyser (Roche Diagnostics Hitachi 917, Hitachi Ltd., Tokyo, Japan). Serum insulin concentration was determined 
by time-resolved luoroimmunoassay using Insulin Kit (AUTOdelia, Wallac, Turku, Finland). HbA1C was meas-
ured by high-pressure liquid chromatography using a fully automated Glycosylated Hemoglobin Analyzer System 
(BioRad, Richmond, CA). Plasma total and HDL cholesterol and triglyceride concentrations were measured with 
respective enzymatic kits from Roche Diagnostics using an autoanalyzer (Roche Diagnostics Hitachi 917, Hitachi 
Ltd., Tokyo, Japan). Serum FFA concentration was measured by an enzymatic colorimetric assay (NEFA-HR(2), 
Wako Chemicals GmbH, Neuss, Germany) using a Konelab 60i analyzer (hermo Electron Corporation, Vantaa, 
Finland). Plasma ALT, AST, GGT and creatinine concentrations were determined as recommended by the 
European Committee for Clinical Laboratory Standards.
Other measurements. Body weight was recorded to the nearest 0.1 kg using a calibrated digital scale 
(Soehnle, Monilaite-Dayton, Finland) with barefoot subjects wearing light indoor clothing. Height and circum-
ferences of waist and hip were recorded to the nearest 0.5 cm using a non-stretchable tape. BMI was deined as 
weight/height2 (kg/m2). Waist circumference was measured midway between the lower rib margin and the iliac 
crest and hip circumference over the greater trochanters. he percentage of body fat was determined using bioelec-
tric impedance analysis (BioElectrical Impedance Analyzer System model #BIA-101A, RJL Systems, Detroit, MI). 
Blood pressure was measured in a sitting position ater a minimum of 15 minutes of acclimatization and before 
blood sampling using an automatic sphygmomanometer (OMRON M7, Omron Healthcare Co. Ltd., Kyoto, Japan).
Statistical analyses. Distribution of continuous variables was tested for normality using the Shapiro-Wilk’s 
normality test. Normally distributed data are shown as mean ± standard error of mean and non-normally distrib-
uted data as median followed by the 25th and 75th percentiles. Changes during follow-up within the study groups 
were analyzed using the paired t-test or Wilcoxon’s matched pairs test, and the groups were compared with the 
unpaired t-test or with the Mann-Whitney’s test, as appropriate. For categorical variables, we used Fisher’s exact 
test or McNemar’s test. We applied logarithmic transformation for non-normally distributed data for Pearson’s 
correlation coeicient and linear regression analyses.
Linear and binary logistic regression analyses were used to identify predictors of liver fat and stifness. Variables 
predicting liver fat and stifness at a signiicance level of <0.05 in univariate analyses were entered in multiple 
linear or backward logistic regression analyses as appropriate. If variables were measures of the same biological 
process (weight/BMI/body fat percent, waist/hip/waist-to-hip ratio, glucose/HbA1C/insulin/HOMA-IR), we only 
included the one most closely associated with outcome of interest. he area under the receiver operating charac-
teristic (ROC) curve (AUROC) of the logistic regression models was used to compare models by the method of 
DeLong et al.48. GraphPad Prism version 6.00 for Mac (GraphPad Sotware, San Diego, CA), IBM SPSS Statistics 
24.0 for Mac (IBM SPSS, Chicago, IL) and the’pROC’ package in R (http://www.R-project.org/) were used to per-
form the statistical analyses. A two-sided p-value of less than 0.05 was considered statistically signiicant.
Data Availability. he data analyzed during the current study are available from the corresponding author 
on reasonable request.
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